Navigation Links
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Date:3/20/2008

the advantage of Avecia's core contract manufacturing business. The sale will focus all Avecia's activities on its core areas of contract manufacture of microbial biologics and oligonucleotides," Adrian Buckmaster, CEO of Avecia commented.

Kevin Price, Senior Vice President Vaccines Business, Avecia Biologics Ltd. commented, "We are confident that the combined capabilities of Avecia and PharmAthene will significantly enhance the overall timeliness and opportunity for success of the development and commercialization programs."

Following completion of the sale and purchase agreement, PharmAthene's biodefense portfolio will include:

-- a recombinant Protective Antigen (rPA) anthrax vaccine

-- Valortim(TM), a fully human monoclonal antibody being co-developed with

Medarex for the prevention and treatment of anthrax infection

-- Protexia(R) a novel bioscavenger to prevent and treat organophosphate

nerve agent poisoning

-- a new type of plague vaccine based on recombinant technology

manufactured in E coli

-- A third generation rPA anthrax vaccine program

rPA Anthrax Vaccine

In February 2008 the Department of Health and Human Services (DHHS) issued a formal solicitation (Request for Proposals) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS). The solicitation outlines a requirement to procure 25 million doses of an rPA anthrax vaccine.

Avecia's rPA vaccine, which has completed Phase II clinical testing, is a second generation rPA anthrax vaccine for use against human anthrax infection. The objective of the program is to develop, through FDA approval, an rPA-based anthrax vaccine that can be stored, transported and used without the need for a conventional cold chain -- an important advantage for civilian biodefense deployment under the Strategic National Stockpile.

"There is currently a tremendous unmet need for a s
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
2. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
3. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
4. PharmAthene to Present at the BIO CEO & Investor Conference 2008
5. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
6. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
10. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
11. Corgenix Signs Technology Licensing Agreement With Japanese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 ... throughput research solutions for biopharmaceutical development, today announced ... - 24, 2014 at GlaxoSmithKline (GSK) in Ware, ... discussions of best practices in high throughput research ... R&D leaders gathered together to discuss the challenges ...
(Date:10/2/2014)... 02, 2014 At a time when many ... has introduced a new kind of squeeze aimed at ... the Scienceware® Squeeze Rite™ Wash Bottle , catalog no. ... within the bottle reduces the waste of reagents, solutions and ... liquids. , “Easier to squeeze when compared to standard 500ml ...
(Date:10/2/2014)... 2, 2014 SIRO Clinpharm, an ... at the prestigious Annual Conference of the Society for ... Vegas , where they were invited to speak ... like ,data analytics to support fraud detection, ,clinical data ... ,benefits of working together as virtual and integrated teams,. ...
(Date:10/1/2014)... Switzerland (PRWEB) October 01, 2014 ... the quality of the final product. However, while ... regulated, regulatory frameworks such as Good Manufacturing Practices ... the responsibility of the manufacturer to interpret these ... consistent weighing performance quality. METTLER TOLEDO experts have ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2
... Senesco Technologies , Inc. ("Senesco" or the "Company") (NYSE ... 2009, the Company entered into a definitive purchase agreement with Partlet ... 1,111,111 shares of its common stock (the "Shares") at a price ... up to 1,000,000 shares of common stock, which warrants are exercisable ...
... its discovery just a few years ago, graphene has ... super-materials poised to transform the electronics and nanotechnology landscape. ... of Arizona State University explains, this two dimensional honeycomb ... Its unusual properties make it ideal for applications that ...
... , KENILWORTH, N.J., July 9 Schering-Plough Corporation ... Schering-Plough K.K., the company,s country operation in Japan, ... mg Tablets for the treatment of major depressive ... Seika Kabushiki Kaisha, Ltd. Schering-Plough and Meiji Seika ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Material world: Graphene's versatility promises new applications 2Material world: Graphene's versatility promises new applications 3Material world: Graphene's versatility promises new applications 4REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 2REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 3REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 4REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 5
(Date:10/2/2014)... CARTES SECURE CONNEXIONS 2014 Conference: A Step Ahead ... SECURE CONNEXIONS 2014 is being held at Paris Nord ... This 29 th  international meeting for the digital security ... together the global community of a constantly evolving sector. ... will set the pace for the event.   ...
(Date:10/1/2014)... discovered a new form of non-genetic inheritance, showing for ... previous sexual partner in flies at least., This ... Greek times, but was discredited in the early 20th ... out, UNSW Australia scientists Dr Angela Crean, Professor Russell ... male flies and studied their offspring., They found that ...
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4Semen secrets: How a previous sexual partner can influence another male's offspring 2Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3
... ease the antibiotic drought, scientists in Massachusetts are describing ... in efforts to discover badly needed new antibiotics. Their ... monthly journal. Frederick Ausubel and colleagues note ... germ-fighting drugs involve adding the potential drug to cultures ...
... Pa., Aug. 4 ComCam International, Inc. (Pink Sheets: CMCJ), ... and services, today announced that it has been selected by ... integration for a Maritime Domain Awareness and Seaport security project. ... stated, "Our two companies have worked informally for about a ...
... paint has been restricted in the United States since ... in major countries from three continents there is still ... to sell consumer paints that contain dangerous levels of ... PhD, and his team have found that approximately 73 ...
Cached Biology News:ComCam Selected by ePortation on New Maritime Domain Awareness Project 2Lead-based consumer paint remains a global public health threat 2Lead-based consumer paint remains a global public health threat 3
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: